Actinium Pharmaceuticals, Inc. (ATNM)
1.57
+0.19
(+13.77%)
USD |
NYAM |
Oct 22, 15:27
Actinium Pharmaceuticals EPS Diluted (Quarterly) : 0.8884 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.8884 |
| March 31, 2026 | -0.1768 |
| December 31, 2025 | -0.1904 |
| September 30, 2025 | -0.1645 |
| June 30, 2025 | -0.2205 |
| March 31, 2025 | -0.5109 |
| December 31, 2024 | -0.2132 |
| September 30, 2024 | -0.3723 |
| June 30, 2024 | -0.3771 |
| March 31, 2024 | -0.3109 |
| December 31, 2023 | -0.3374 |
| September 30, 2023 | -0.4906 |
| June 30, 2023 | -0.579 |
| March 31, 2023 | -0.4295 |
| December 31, 2022 | -0.4147 |
| September 30, 2022 | -0.3765 |
| June 30, 2022 | -0.3273 |
| March 31, 2022 | -0.2316 |
| December 31, 2021 | -0.3617 |
| September 30, 2021 | -0.2982 |
| June 30, 2021 | -0.2482 |
| March 31, 2021 | -0.2895 |
| December 31, 2020 | -0.3748 |
| September 30, 2020 | -0.359 |
| June 30, 2020 | -0.4065 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.9831 |
| December 31, 2019 | -0.8382 |
| September 30, 2019 | -1.212 |
| June 30, 2019 | -0.9954 |
| March 31, 2019 | -1.451 |
| December 31, 2018 | -1.651 |
| September 30, 2018 | -1.670 |
| June 30, 2018 | -1.20 |
| March 31, 2018 | -2.145 |
| December 31, 2017 | -1.80 |
| September 30, 2017 | -2.70 |
| June 30, 2017 | -3.60 |
| March 31, 2017 | -4.20 |
| December 31, 2016 | -3.60 |
| September 30, 2016 | -4.20 |
| June 30, 2016 | -4.276 |
| March 31, 2016 | -3.00 |
| December 31, 2015 | -4.453 |
| September 30, 2015 | -3.00 |
| June 30, 2015 | -6.00 |
| March 31, 2015 | -2.70 |
| December 31, 2014 | -5.431 |
| September 30, 2014 | -6.30 |
| June 30, 2014 | 3.00 |
| March 31, 2014 | -19.80 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 27.90M |
| Revenue (Quarterly) | 35.00M |
| Total Expenses (Quarterly) | 7.099M |
| Enterprise Value | 8.257M |
| Gross Profit Margin (Quarterly) | 98.77% |
| Profit Margin (Quarterly) | 79.72% |
| Earnings Yield | 22.72% |
| Operating Earnings Yield | 19.47% |
| Normalized Earnings Yield | 22.72 |